Methods to inhibit growth of prostate cancer cells

US7361338B2 · kind B2 · utility

Assignee

• Latency, LLC · US

Inventors

• Aya Jakobovits · Beverly Hills, US
• Mary Faris · Los Angeles, US
• Arthur B. Raitano · Los Angeles, US
• Robert Kendall Morrison · Santa Monica, US
• Douglas Saffran · Los Angeles, US
• Wangmao Ge · Tampa, US
• Pia M. Challita-Eid · Calabasas, US

Key dates

• Filing date: May 15, 2002
• Grant date: Apr 22, 2008
• Expiry date: Jul 11, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/34
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.